1. Home
  2. LEN vs ALNY Comparison

LEN vs ALNY Comparison

Compare LEN & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lennar Corporation

LEN

Lennar Corporation

SELL

Current Price

$83.80

Market Cap

21.1B

ML Signal

SELL

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

SELL

Current Price

$159.75

Market Cap

21.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LEN
ALNY
Founded
1954
2002
Country
United States
United States
Employees
N/A
115
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1B
21.6B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
LEN
ALNY
Price
$83.80
$159.75
Analyst Decision
Sell
Buy
Analyst Count
21
30
Target Price
$77.27
★ $299.96
AVG Volume (30 Days)
★ 3.6M
3.1M
Earning Date
12-15-2026
10-29-2026
Dividend Yield
★ 2.39%
N/A
EPS Growth
N/A
★ 206.88
EPS
3.36
★ 18.42
Revenue
★ $34,186,934,000.00
$1,037,418,000.00
Revenue This Year
N/A
$46.57
Revenue Next Year
$1.12
$19.91
P/E Ratio
$24.87
★ $8.93
Revenue Growth
N/A
★ 22.88
52 Week Low
$71.78
$149.18
52 Week High
$133.76
$479.79

Technical Indicators

Market Signals
Indicator
LEN
ALNY
Relative Strength Index (RSI) 48.35 31.82
Support Level $82.96 N/A
Resistance Level $84.25 $237.47
Average True Range (ATR) 3.12 10.64
MACD -0.65 -0.10
Stochastic Oscillator 11.11 12.91

Price Performance

Historical Comparison
LEN
ALNY

About LEN Lennar Corporation

Lennar is the second-largest public homebuilder in the United States, behind D.R. Horton, operating in 26 states. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: